Belite Bio, Inc
NASDAQBLTE short interest falls 20.9% in one week to 1.12M shares, down from 1.43M on Aug 6, as shorts retreat ahead of earnings; availability stands at 162%, cost to borrow 0.67%.
Belite Bio reports this afternoon with shorts visibly retreating — short interest dropped 21% in a single session on August 11 to around 1.13 million shares, capping a week in which the stock climbed 13% to $177.58 and…
BLTE arrives at tomorrow's earnings print on the back of its strongest monthly run in recent memory, with the stock up 19% over the past month and 13% in the last week alone to close at $177.58. The borrow market tells…
Snapshot as of 19 Aug 2026
Belite Bio has cleared its Q1 earnings hurdle but the stock has not stopped falling — down 10% on the week to $139.70, extending a 16% one-month retreat that predates the print. The Q1 result itself delivered the…
BLTE heads into tomorrow's Q1 earnings with short sellers building positions aggressively — and a stock that has given back nearly 17% in a month. The sharpest signal heading into the May 20 report is the jump in short…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for BLTE — free to start on ORTEX.
Sign up for free →Open BLTE on ORTEX